tacc3

KHS101 is a novel inhibitor of transforming acidic coiled-coil protein 3 (TACC3). It is a selective inducer of neuronal differentiation.

KHS101 is a TACC3 inhibitor and can selectively induce a neuronal differentiation phenotype.

BO-264 is a highly potent and orally active inhibitor of transforming acidic coiled-coil 3 (TACC3) with an IC50 of 188 nM and a Kd of 1.5 nM.

SNIPER(TACC3)-1 targets TACC3 protein degradation via the ubiquitin-proteasome pathway.It induces cancer cell death.

SNIPER(TACC3)-2 targets TACC3 protein degradation via the ubiquitin-proteasome pathway. It induces cancer cell death.

TACC3 inhibitor 2 (Compound 13b) is a TACC3 inhibitor with an IC50 of 200 nM. It induces mitotic arrest, apoptosis (Apoptosis), and DNA damage. TACC3 inhibitor 2 is applicable for research in the field of cancer.

TACC3 inhibitor 1 is a potent agent capable of crossing the blood-brain barrier, inducing apoptosis and cell cycle arrest at the G2/M phase, and generating intracellular ROS (reactive oxygen species). It exhibits significant antiproliferative and anti-tumor activity.

SNIPER(TACC3)-11 is a potent degrader of the FGFR3-TACC3 protein, significantly reducing its levels and inhibiting the proliferation of FGFR3-TACC3-positive cancer cells [1].

SNIPER(TACC3)-2 hydrochloride is a compound that induces degradation of the TACC3 protein through the ubiquitin-proteasome pathway by exploiting an IAP ligand, leading to the induction of cancer cell death [1].

SNIPERTACC3-1 hydrochloride, an IAP ligand-based compound, selectively degrades the TACC3 protein through the ubiquitin-proteasome pathway, thereby inducing cancer cell apoptosis [1].

LC-MF-4 is a selective FGFR3 PROTAC degrader with a DC50 of 30.89 nM in KMS-11 cells. It inhibits the metabolic functions of FGFR3-TACC3 fusion-positive cancers by reducing ATP synthesis and suppressing mitochondrial biogenesis genes. LC-MF-4 demonstrates potent anti-tumor activity in the Ba/F3-FGFR3-TACC3 xenograft mouse model and is applicable for research on FGFR3 gene mutation cancers such as bladder cancer and urothelial carcinoma (UC).

KG-548 is a dual inhibitor of ARNT/TACC3 and HIF-1α, binding to the β-fold surface involved in HIF-2 dimerization and coactivator recruitment, inhibiting lactate production and useful in cancer research.

KG-655 is a small molecule compound that binds to the β-sheet surface and internal cavity of ARNTPAS-B, disrupting its interaction with the transcription coactivator TACC3. This compound facilitates the homodimerization of ARNTPAS-B and has the potential to regulate multiple ARNT-mediated signaling pathways.